



Edgar Filing: AGENUS INC - Form 8-K

On April 6, 2011, Agenus Inc. announced that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent glioma will be presented in a poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting. The meeting will be held in Chicago, IL, June 3rd -7th.

The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated April 6, 2011

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AGENUS INC.**

---

(Registrant)

/s/ **SHALINI SHARP**

---

**April 6, 2011**

(Date)

---

Shalini Sharp  
*Chief Financial Officer*

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated April 6, 2011